海科公司

最新新闻

• 公司公告
  Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. Regarding the Receipt of the Clinical Trial Approval Notice for Hei Huang Chi Zhu Granules
  SZSI · 2026/2/26
• 评级变动
  Goldman Sachs Maintains Heico(HEI.US) With Buy Rating, Raises Target Price to $491
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  Wells Fargo Maintains Heico(HEI.US) With Hold Rating, Cuts Target Price to $335
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Morgan Stanley Maintains Heico(HEI.US) With Hold Rating, Cuts Target Price to $365
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Jefferies Maintains Heico(HEI.US) With Buy Rating, Maintains Target Price $430
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• TD Cowen Maintains Heico(HEI.US) With Hold Rating, Cuts Target Price to $330
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• On October 8, Zhou Hei Ya (01458) repurchased 207,000 shares at a total cost of approximately HK$220,200.
  Zhitong Finance · 2026/10/8
• 公司公告
  Hawaiian Electric Industries | 8-K: On May 8, 2026, HEI issued a news release, “HEI Reports First Quarter 2026 Results.” This news release is furnished as HEI Exhibit 99.
  SEC · 2026/5/9
• 评级变动
  William Blair Maintains Heico(HEI.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• Citi Maintains Heico(HEI.US) With Buy Rating, Maintains Target Price $441
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• SIG Maintains Heico(HEI.US) With Hold Rating, Maintains Target Price $365
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Melius Research Initiates Heico(HEI.US) With Hold Rating, Announces Target Price $350
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  A Quick Look at Today's Ratings for Heico(HEI.US), With a Forecast Between $365 to $441
  \u5e02\u573a\u8d44\u8baf · 2026/8/28
• On October 7, Zhou Hei Ya (01458.HK) repurchased 374,000 shares at a cost of HK$393,000.
  Gelonghui Finance · 2026/10/7
• 评级变动
  BofA Securities Maintains Heico(HEI.US) With Buy Rating, Maintains Target Price $400
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 公司公告
  Kangyuan Pharmaceutical: Announcement of Jiangsu Kangyuan Pharmaceutical Co., Ltd. Regarding the Receipt of the Clinical Trial Approval Notice for Hei Huang Chi Zhu Granules
  SZSI · 2026/2/26
• 评级变动
  Citi Maintains Heico(HEI.US) With Buy Rating, Raises Target Price to $441
  \u5e02\u573a\u8d44\u8baf · 2026/8/29
• 评级变动
  Truist Financial Initiates Heico(HEI.US) With Buy Rating, Announces Target Price $412
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 公司公告
  Barcos: We provided special sponsorship for the 41st Kurayoshi Women's Ekiden Race, the "Chūhei Nanbu Cup."
  JPX · 2026/10/6
• 公司公告
  Hawaiian Electric Industries | 8-K: On February 27, 2026, HEI issued a news release, “HEI Reports Fourth Quarter and Full Year 2025 Results.” This news release is furnished as HEI Exhibit 99.
  SEC · 2026/2/28
• 公司公告
  Hawaiian Electric Industries | 8-K: On November 7, 2025, HEI issued a news release, “HEI Reports Third Quarter 2025 Results.” This news release is furnished as HEI Exhibit 99.
  SEC · 2025/11/8
• Zhou Hei Ya (01458) repurchased 268,000 shares on September 21 for HK$295,100.
  Zhitong Finance · 2026/9/21
• 评级变动
  A Quick Look at Today's Ratings for Heico(HEI.US), With a Forecast Between $390 to $430
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• Zhou Hei Ya (01458.HK) repurchased 501,000 shares on September 29 at a total cost of HK$533,700.
  Gelonghui Finance · 2026/9/29
• On September 28, Zhou Hei Ya (01458.HK) repurchased 303,000 shares at a total cost of HK$322,200.
  Gelonghui Finance · 2026/9/28

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。